Sperogenix Acquires Rights in China to Develop ABSK021

Sperogenix Acquires Rights in China to Develop ABSK021

300128

Sperogenix Acquires Rights in China to Develop ABSK021

A subsidiary of Sperogenix Therapeutics has acquired exclusive rights to develop and commercialize ABSK021, an investigational oral therapy for amyotrophic lateral sclerosis (ALS) and other rare neurological diseases in mainland China, Hong Kong, and Macao. Under the terms of the agreement between Sperogenix MedTech and Abbisko Therapeutics, the therapy’s developer, Abbisko will receive an upfront payment from Sperogenix and will be eligible for additional milestone and royalty payments. The company will retain rights to ABSK021 in all…

You must be logged in to read/download the full post.